Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Nishant Sethi

Interventional Cardiology Scranton, PA Medical Doctor

NPI 1306070735 CMS profile 1380417

743 Jefferson Ave, Suite 305, Scranton, PA 18510

Open in the dashboard

General payments

$1,335,809

1,667 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Nishant Sethi of Scranton, PA is reported in the CMS Open Payments database as having received $1,335,809 across 1,667 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $269,153 325
2024 General $315,999 295
2023 General $120,424 203
2022 General $125,680 214
2021 General $221,257 248
2020 General $122,021 147
2019 General $161,275 235

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Nishant Sethi
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Nishant Sethi were reported at $269,153. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Nishant Sethi Interventional Cardiology median Middle half National median
2019 $161,275 $1,097 $329–$3,048 $163
2020 $122,021 $473 $161–$1,480 $114
2021 $221,257 $677 $233–$1,827 $132
2022 $125,680 $978 $333–$2,724 $149
2023 $120,424 $1,136 $382–$2,986 $160
2024 $315,999 $1,181 $395–$3,326 $164
2025 $269,153 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $723,752 687 payments
  2. Medtronic Vascular, Inc. $281,618 330 payments
  3. Abbott Laboratories $231,897 202 payments
  4. Edwards Lifesciences Corporation $75,512 193 payments
  5. Bard Peripheral Vascular, Inc. $13,744 13 payments
  6. Boston Scientific Corporation $4,011 74 payments
  7. Abiomed $1,131 19 payments
  8. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $1,010 14 payments
  9. E.R. Squibb & Sons, L.L.C. $739 28 payments
  10. Novartis Pharmaceuticals Corporation $712 48 payments
  11. Other $1,685 59 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $808,656 225 payments
  2. Travel and Lodging $286,699 580 payments
  3. Consulting Fee $168,938 55 payments
  4. Food and Beverage $44,361 797 payments
  5. Compensation for serving as faculty or as a speaker for a medical education program $27,000 7 payments
  6. Education $87 2 payments
  7. Debt forgiveness $68 1 payment
Products named General payments · program years 2019–2025
  1. COREVALVE EVOLUT R $489,365 439 payments
  2. CoreValve Evolut Transcatheter Valve Systems $280,869 319 payments
  3. CoreValve Evolut Transcatheter Valve Systems $219,430 202 payments
  4. NAVITOR Vascular $142,344 103 payments
  5. NAVITOR Structural Heart $85,934 72 payments
  6. EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) $63,349 49 payments
  7. RESOLUTE ONYX $12,514 20 payments
  8. PASCAL $3,400 14 payments
  9. Edwards SAPIEN 3 Ultra Transcatheter Heart Valve $2,008 28 payments
  10. SAPIEN 3 Ultra RESILIA $1,868 17 payments
  11. Other $17,085 353 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 31 drugs

Part D claims

2,227

Median for Interventional Cardiology: 2,236

Drug cost

$286,876

Median for Interventional Cardiology: $380,412

Branded share of claims

39.6%

Median for Interventional Cardiology: 27.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 172 $144,487
Entresto Sacubitril/Valsartan Brand 92 $93,510
Xarelto Rivaroxaban Brand 16 $14,955
Brilinta Ticagrelor Brand 13 $10,604
Metoprolol Succinate Generic 234 $3,590
Clopidogrel Clopidogrel Bisulfate Brand 375 $3,057
Atorvastatin Calcium Generic 226 $2,493
Isosorbide Mononitrate Er Isosorbide Mononitrate Brand 94 $1,732
Warfarin Sodium Generic 89 $1,517
Rosuvastatin Calcium Generic 79 $1,412

The 10 drugs with the highest cost, of 31 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 4,694 Part D prescribers listed as Interventional Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 93 billing codes

Paid by Medicare

$218,491

Medicare's payments for the services billed

Medicare patients

537

Average age 77

Services billed

2,820

242 women, 295 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 75%
Arthritis 58%
Heart failure 52%
Atrial fibrillation 42%
Diabetes 41%
Chronic kidney disease 35%
COPD 23%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 7 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ELIQUIS
$90 172 —
LEQVIO
$85 — —
ENTRESTO
$85 92 —
CAMZYOS
$81 — —
JARDIANCE
$20 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 7 in the dashboard with a free account

Records

1,667 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Cardiology in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record